Therapeia - Glioblastoma Program's Unit Acquisition

Therapeia - Glioblastoma Program raised a round of funding on January 19, 2017. Investors include Telix Pharmaceuticals.

Therapeia was ounded by Dr. Andreas Kluge, it is developing ACD101, a synthetic amino acid, for both imaging and therapy, in several important oncology settings.…

Articles about Therapeia - Glioblastoma Program's Unit Acquisition: